Rationale for vaccination with trivalent or quadrivalent live attenuated influenza vaccines: Protective vaccine efficacy in the ferret model-Reference-Cited by-同舟云学术

Rationale for vaccination with trivalent or quadrivalent live attenuated influenza vaccines: Protective vaccine efficacy in the ferret model

Published:2018-12-03 Issue:12 Volume:13 Page:e0208028
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Rudenko Larisa,Kiseleva Irina^ORCID,Krutikova Elena^ORCID,Stepanova Ekaterina^ORCID,Rekstin Andrey,Donina Svetlana^ORCID,Pisareva Maria,Grigorieva Elena^ORCID,Kryshen Kirill^ORCID,Muzhikyan Arman^ORCID,Makarova Marina^ORCID,Sparrow Erin Grace,Torelli Guido,Kieny Marie-Paule

Funder

World Health Organization

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference61 articles.

1. Distribution of influenza virus types by age using case-based global surveillance data from twenty-nine countries, 1999–2014;S Caini;BMC Infect Dis,2018

2. The burden of influenza B: a structured literature review;W Paul Glezen;Am J Public Health,2013

3. Reappearance and global spread of variants of influenza B/Victoria/2/87 lineage viruses in the 2000–2001 and 2001–2002 seasons;MW Shaw;Virology,2002

4. Phylogenetic and evolutionary history of influenza B viruses, which caused a large epidemic in 2011–2012, Taiwan;JR Yang;PLoS One,2012

5. Global circulation patterns of seasonal influenza viruses vary with antigenic drift;T Bedford;Nature,2015

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The glycobiology of microbial infectious disease;Translational Glycobiology in Human Health and Disease;2024

2. Murine Broadly Reactive Antineuraminidase Monoclonal Antibodies Protect Mice from Recent Influenza B Virus Isolates and Partially Inhibit Virus Transmission in the Guinea Pig Model;mSphere;2022-10-26

3. Immunogenicity and safety of an egg culture-based quadrivalent inactivated non-adjuvanted subunit influenza vaccine in subjects ≥3 years: A randomized, multicenter, double-blind, active-controlled phase III, non-inferiority trial;Vaccine;2022-08

4. COVID-19 Vaccine Booster Strategies for Omicron SARS-CoV-2 Variant: Effectiveness and Future Prospects;Vaccines;2022-07-30

5. Nasal vaccine as a booster shot: a viable solution to restrict pandemic?;Clinical and Experimental Vaccine Research;2022